Accuryn Medical

Accuryn Medical (formerly known as Potrero Medical) specializes in addressing hospital-acquired acute kidney injury (AKI). The company's flagship product is the Accuryn Monitoring System, which enables real-time renal assessment and early intervention for AKI. This system includes proprietary Active Drain Line technology and software solutions like AKI Detect, which detects oliguric AKI, providing clinicians with early notification of kidney distress compared to the standard serum creatinine test.

The Accuryn Monitoring System transforms traditional urinary catheters into smart sensors capable of real-time continuous monitoring of urine output, intra-abdominal pressure (IAP), and core body temperature. This integrated physiological data provides insights into patients' fluid status and organ perfusion, enabling critical care clinicians to intervene early and disrupt disease state progression associated with iatrogenic AKI.

In September 2022, the FDA granted breakthrough device designation to its AKI Predict machine learning algorithm for advanced prediction of AKI associated with intra-abdominal hypertension in cardiac post-surgical intensive care patients.

In February 2024, after completing a comprehensive restructuring and oversubscribed equity offering, the company launched software upgrades to enhance its AKI detection capabilities and expanded its product portfolio by introducing 10 new Foley catheter sizes to cater to a wider range of patients. These sizes are all designed to reduce the risks associated with catheter-associated urinary tract infections.

Key customers and partnerships

Accuryn Medical serves various sectors within the healthcare industry, particularly focusing on hospitals and intensive care units. The company had treated nearly 70,000 patients as of February 2024. Notable customers included Mayo Clinic and the University of Michigan Health.